The Court of Appeal for England and Wales has ruled that clinical commissioning groups (CCGs) can offer Roche’s Avastin (bevacizumab) to patients with wet age-related macular degeneration, even though it is not licensed for that indication.
In doing so the court has finally put an end to a long-running effort by Novartis and Bayer to prevent Avastin, which is approved as an anticancer drug, from being...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?